Abstract：Objective: To discuss the correlation between peripheral blood PD-1, Th1/Th2, Th17/Treg and atopic dermatitis (AD). Methods: A total of 90 AD patients admitted to our hospital from Jun 2022 to Feb 2024 were selected as the study subjects, and divided into the moderate group (SCORAD severity index score 25-50, 51 cases) and the severe group (SCORAD score>50, 39 cases) based on the severity of the AD condition. Additionally, 50 non-AD patients admitted to our hospital during the same period were selected as the control group. Recorded and analyzed the eczema area and severity index (EASI) score, SCORAD, patient self-evaluation (POEM) and itching score of AD patients, as well as peripheral blood PD-1, Th1/Th2, Th17/Treg values. Spearman rank correlation analysis was used to explore the correlation between the two variables, and ROC curve was used to evaluate the effectiveness of PD-1, Th1/Th2 and Th17/Treg in predicting the severity of AD. Results: The scores of EASI (13.94±3.35), SCORAD (57.02±6.78), POEM (24.11±3.12) and pruritus severity score (8.98±1.03) of the severe group were higher than the moderate group (t-values were 6.444,7.638,9.133,8.873 respectively, P<0.05). The PD-1 (285.63±34.78) pg/ml, Th17 (9.65±1.97)%, Treg (2.71±1.04)% and Th17/Treg (3.62±0.69) of the severe group were higher than the moderate group, while Th1 (7.89±0.79)%, Th2 (2.34±0.45)%, and Th1/Th2 (3.21±0.57) were lower than the moderate group (P<0.05). The results of multiple logistic regression analysis showed that EASI score, SCORAD score, POEM score, itch severity score, PD-1, Th1/Th2, and Th17/Treg were independent risk factors for the severity of AD patients (all P<0.05). The PD-1 and Th17/Treg were positively correlated with EASI, SCORAD, POEM and itching severity scores (P<0.05); while the Th1/Th2 was negatively correlated with EASI, SCORAD, POEM and itching severity scores (P<0.05). The AUC value of PD-1+Th1/Th2+Th17/Treg combined prediction for the severity of AD was 0.979, with the sensitivity 94.87% and the specificity of 96.08%, which indicating that PD-1+Th1/Th2+Th17/Treg combined prediction had a higher efficiency in predicting the severity of AD. Conclusion: Peripheral blood PD-1, Th17/Treg levels were significantly increased and Th17/Treg levels were significantly decreased in AD patients, while peripheral blood PD-1, Th17/Treg levels were significantly increased and decreased in severe AD patients. PD-1, Th1/Th2 and Th17/Treg levels were closely related to the severity of AD. The combined detection of PD-1+Th1/Th2+Th17/Treg can improve the evaluation of AD severity.
孙晓琳, 吕承秀, 苗传玉, 宋波, 李庆, 吕岩. 外周血PD-1 Th1/Th2及Th17/Treg与特应性皮炎的相关性研究[J]. 河北医学, 2025, 31(3): 464-469.
SUN Xiaolin, LV Chengxiu, et al. The Study on the Correlation between Peripheral Blood Pd-1 Th1/Th2 Th17/Treg and Atopic Dermatitis. HeBei Med, 2025, 31(3): 464-469.
[1] 贾韬,车德路,郑义,等.肥大细胞参与特应性皮炎表型及2型炎症因子释放的免疫活化中作用的初步研究[J].中华医学杂志,2023,103(32):2502-2508. [2] Pezzolo E,Sechi A,Tartaglia J,et al.A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults[J].Expert Rev Clin Immunol,2024,20(3):255-266. [3] 陈田恬,黄显博,闵瑾雯,等.特应性皮炎患者外周血调节性T细胞亚群及相应细胞因子的表达[J].广东医学,2023,44(9):1104-1109. [4] Schmid-Grendelmeier P,Gooderham MJ,Hartmann K,et al.Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies[J].Allergy,2024,79(1):174-183. [5] 中华医学会皮肤性病学分会,中国医师协会皮肤科医师分会.中国中重度特应性皮炎诊疗临床路径专家共识(2023版)[J].中华皮肤科杂志,2023,56(11):1000-1007. [6] Bridgeman SG,Martino AK,Strowd LC.Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis[J].Expert Opin Pharmacother,2023,24(18):2153-2159. [7] 李媛,郑蕾,陈冬.血清IgE、IFN-γ及Th17细胞因子水平与成人特应性皮炎病情严重程度的相关性[J].武汉大学学报(医学版),2023,44(10):1240-1243,1261. [8] Kim JW,Kim MJ,Paik K,et al.Genome-wide association study of susceptibility loci for self-reported atopic dermatitis and allergic rhinitis in the korean population[J].Ann Dermatol,2024,36(2):74-80. [9] Bardazzi F,Pilrri A,ClarizioO G,et al.Psoriasis dermatitis:a new entity or a different phenotypic expression of psoriasis and atopic dermatitis[J]Ital Dermatol Venerol,2024,159(2):166-173. [10] 陈淼,王晓敏,覃李玲,等.特应性皮炎患者血清SIRT1和STAT3水平与病情严重程度的相关性分析[J].标记免疫分析与临床,2023,30(8):1367-1372. [11] Woo YR,Choi A,Song SW,et al.Risk of developing hypertension in atopic dermatitis patients receiving long-term and low-dose cyclosporine:a nationwide population-based cohort study[J].Ann Dermatol,2024,36(2):112-119. [12] Issa N,Kwong P,G Bunick C,et al.Individual article:appraisal of ruxolitinib 1.5% cream as a first-line topical therapeutic agent for adolescents and adults with mild-to-moderate atopic dermatitis[J].J Drugs Dermatol,2025,24(2):5-15. [13] 王钰,李巍.特应性皮炎外周血单个核细胞转录组特征及其在度普利尤单抗疗效预测中的应用[J].中华临床免疫和变态反应杂志,2023,17(5):505-511. [14] 林颖,刘颖瑶,张彩云,等.基于16S rRNA测序探讨特应性皮炎湿证特征与皮肤菌群的相关性[J].中华中医药杂志,2023,38(11):5504-5509. [15] 王晓晨,陈露,刘畅,等.基于生物信息学方法筛选特应性皮炎关键基因和相关药物预测[J].江汉大学学报(自然科学版),2024,52(2):46-55.
2025, Vol. 31 
冀公网安备13080202000786号